Scienture Holdings, Inc. SCNX 深 滬
等待開盤 06-25 09:30:00 美东时间
0.3683
-0.014
-3.56%
華盛通- 最 高0.3843
- 今 開0.3816
- 成交量 19.49万股
- 最 低 0.366
- 昨 收 0.3819
- 總市值 1496.43万
- 52周最高 2.60
- 市盈率 靜 --
- 換手率 0.48%
- 52周最低 0.2382
- 委 比 86.89%
- 總股本 4063.08万
- 歷史最高 164.50
- 量 比 0.44
- 振 幅 4.79%
- 歷史最低 -5.81
- 每 手 1
- 風險率 0.51%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多EXCLUSIVE: SCIENTURE Secures Formulary Coverage For REZENOPY; Commercial Launch Planned For Mid-July
5,000+ Healthcare Facilities Reached ThroughGPO Agreements, Covering ~60% of Institutional GPO MarketU.S. naloxone market totals ~$144 million in annual sales and ~9.8 million units annually,represents significant
06-09 19:45
Scienture Holdings Q1 EPS $(0.08) Beats $(0.22) Estimate, Sales $56.325K Up From $10.258K YoY
Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.22) by 63.64 percent. This is a 75.76 percent increase over losses of $(0.33) per share
05-16 06:12
SCIENTURE HOLDINGS Secures $11M In Non-Dilutive Debt Financing Through Note Purchase Agreement With Institutional Investor
Proceeds support commercialization of Arbli™, the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY™, life-saving opioid overdose emergency treatmentFinancing also drives early-
05-07 20:20
USPTO Issued SCIENTURE HOLDINGS U.S. Patent No. 12,605,365, Titled "Losartan Liquid Formulations and Methods of Use,"
U.S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a significant opportunity for ARBLI™ as the first FDA-approved ready-to-use oral suspension
05-06 20:08
Scienture Awarded $950K U.S. Department Of Veterans Affairs Pharmaceutical Supply Contract, Pharmaceutical Preparation Manufacturing
https://sam.gov/opp/cd98e3d515624c65afe83187b80993a7/view
04-28 01:05
SCIENTURE HOLDINGS Gets 180‑Day Nasdaq Extension; Compliance Deadline Now October 12
SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture") a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through
04-15 20:15
Scienture Holdings shares are trading lower. The company reported FY25 financial results.
Scienture Holdings shares are trading lower. The company reported FY25 financia...
03-31 02:02
EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025
Scienture reports 216% revenue growth in 2025, driven by Arbli uptake, patent wins, and expanded healthcare access across the US.
03-30 19:46
EXCLUSIVE: Scienture Expands Reach For Opioid Overdose Treatment, With Deals Covering 60% Of US Institutional Market
Scienture signs agreements expanding Rezenopy naloxone for opioid overdose access to 5,000 US institutions and first responders.
03-11 19:46
